LEO Pharma
leo-pharma.comTotal trials
222
Active
4
Phase 3
53
Total enrollment
169,393
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 5 of 5 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Delgocitinib | — | — | — | 8 | |||
| Cream vehicle | — | — | — | 6 | |||
| Tralokinumab + TCS | — | — | — | — | — | 1 | |
| Delgocitinib cream | — | — | — | 9 | |||
| Vehicle cream | — | — | — | — | 2 |
Next readouts
- 2026-10-20
- 2026-12-14
- 2028-03-10
Top conditions
- Psoriasis Vulgaris59
- Atopic Dermatitis34
- Actinic Keratosis29
- Healthy17
- Chronic Hand Eczema9
- Papulopustular Rosacea6
- Psoriasis5
- Plaque Psoriasis4
Frequently asked questions about LEO Pharma
- How many clinical trials does LEO Pharma have on ClinicalTrials.gov?
- LEO Pharma is listed as the lead sponsor on 222 clinical trials in ClinicalTrials.gov, 4 of which are currently active (recruiting, enrolling, or ongoing).
- How many of LEO Pharma's trials are in Phase 3?
- 53 of LEO Pharma's trials are in Phase 3, spread across 5 active drug programs.
- What therapeutic areas does LEO Pharma focus on?
- LEO Pharma's most-studied conditions on ClinicalTrials.gov are Psoriasis Vulgaris, Atopic Dermatitis, Actinic Keratosis, Healthy, Chronic Hand Eczema.
- When are LEO Pharma's next clinical trial readouts?
- LEO Pharma has 3 upcoming primary-completion readouts tracked here; the soonest is “A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis”, expected around 2026-10-20.